International Stem Cell Corporation is Valued at $6.16 per Share by Edison Investment Research
05 Dicembre 2018 - 2:30PM
InvestorsHub NewsWire
International
Stem Cell Corporation is Valued at $6.16 per Basic Share by Edison
Investment Research
CARLSBAD, CA -- December 5, 2018 --
InvestorsHub NewsWire -- International Stem Cell Corporation
(OTCQB:ISCO)
(www.internationalstemcell.com)
("ISCO" or "the Company"), a California-based clinical stage
biotechnology company developing novel stem cell-based therapies
and biomedical products, today announced that Edison Investment
Research Inc. (“Edison”)* has valued ISCO at $42 million or $6.16
per basic share, up from $36 million or $5.72 per basic share, in a
research note published on December 4,
2018.
The research note, along with all Edison’s research
on the Company, is freely-available on Edison’s website and the
report can be accessed here: https://www.edisoninvestmentresearch.com/research/report/international-stem-cell-192233/full
The research note highlights ISCO’s strong third
quarter 2018 revenues, which were $3.2 million, an increase of 73%
year-on-year. The note also highlights ISCO’s encouraging initial
Phase I clinical results in Parkinson’s Disease
(PD).
About International Stem Cell
Corporation
International Stem Cell Corporation is focused on
the therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com),
and stem cell-based skin care products through its subsidiary
Lifeline Skin Care (www.lifelineskincare.com). More
information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate
communications, please click on the following
link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter
for company updates and industry related news,
visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
*The Edison report was sponsored by the
Company.
Safe harbor
statement
Statements pertaining to anticipated developments,
expected pre-clinical studies (including timing and results),
progress of research and development, and other opportunities for
the Company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements. Any
statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates,") should also be
considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential products, regulatory approvals, need
and ability to obtain future capital, application of capital
resources among competing uses, and maintenance of intellectual
property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the Company's business, particularly those mentioned in the
cautionary statements found in the Company's Securities and
Exchange Commission filings. The Company disclaims any intent or
obligation to update forward-looking
statements.
Contact:
Dr. Russell Kern
EVP, Chief Scientific Officer
(760) 940-6383
ir@intlstemcell.com
Grafico Azioni International Stem Cell (QB) (USOTC:ISCO)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni International Stem Cell (QB) (USOTC:ISCO)
Storico
Da Dic 2023 a Dic 2024
